Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001171843-23-006869
Filing Date
2023-11-08
Accepted
2023-11-08 16:29:53
Documents
6
Effectiveness Date
2023-11-08

Document Format Files

Seq Description Document Type Size
1 FORM S-8 s8_110823.htm S-8 30917
2 EXHIBIT 5.1 exh_51.htm EX-5.1 8719
3 EXHIBIT 23.1 exh_231.htm EX-23.1 2620
4 EXHIBIT 107 exh_107.htm EX-FILING FEES 13602
5 GRAPHIC gdc.jpg GRAPHIC 36945
6 GRAPHIC gdc_logo.jpg GRAPHIC 25964
  Complete submission text file 0001171843-23-006869.txt   143665
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-275401 | Film No.: 231388338
SIC: 2836 Biological Products, (No Diagnostic Substances)